Physician profile
Julia B Ritsan
NPI 1730178054
$7,463.33
in general payments reported to CMS, 2019-2025
35 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $1,215 · 2021: $1,103 · 2022: $1,121 · 2023: $851 · 2024: $943 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,300.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $944.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.34 | 2019-2023 | Jardiance |
| Abbvie INC. | $452.37 | 2021-2024 | Qulipta, Ubrelvy |
| Amarin Pharma, INC. | $323.09 | 2019-2022 | |
| Lilly USA, LLC | $289.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $150.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $130.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $125.45 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $108.14 | 2019-2021 | |
| Dexcom, INC. | $105.54 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $97.97 | 2019-2024 | |
| Amgen INC. | $81.53 | 2021-2022 | |
| Daiichi Sankyo INC. | $81.33 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.71 | 2023-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $65.14 | 2020 | |
| Sanofi-Aventis U.S. LLC | $52.53 | 2019-2023 | |
| Exact Sciences Corporation | $51.47 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $49.99 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $48.27 | 2019-2022 | |
| Phadia US INC. | $48.10 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $42.97 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.31 | 2019-2023 | Xifaxan |
| Sanofi Pasteur INC. | $40.71 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.37 | 2019-2022 | |
| Axsome Therapeutics, INC. | $37.58 | 2025 | Symbravo |
| Ibsa Pharma INC. | $30.72 | 2022-2024 | Licart, Tirosint |
| Esperion Therapeutics, INC. | $29.12 | 2020-2023 | Nexletol |
| Genentech USA, INC. | $28.21 | 2021-2022 | |
| Irhythm Technologies, INC. | $25.51 | 2022 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.93 | 2022 | |
| Allergan, INC. | $14.52 | 2019 | |
| Clarus Therapeutics INC. | $14.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Ritsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.